Jaros, Mark

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 1,665

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 818

NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 425

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 262

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 229

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial

Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 116

Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials

Carbohydrate and Lipid Metabolism Research Unit, F. O. H. S., Raal, F., Ableson, M., Vergelegen Mediclinic, S. W., Blignaut, S., Paarl Research Centre, P., Burgess, L., Tread Research, C. U., Coetzer, S., Accelerated Enrollment Solutions, H. C. R. C., et al. (2022) · South African Medical Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 14

BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder

Papapetropoulos, S., Doolin, E., O’Connor, S., Paul, D., Odontiadis, M., Jaros, M., Rolan, P., & Stein, M. B. (2025) · NEJM Evidence

Posttraumatic Stress Disorder ResearchNicotinic Acetylcholine Receptors Study

Cited by 5

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

Koenig, W., Ray, K. K., Kallend, D. G., Landmesser, U., Leiter, L. A., Schwartz, G. G., Wright, R. S., Garcia Conde, L., Jaros, M., & Raal, F. J. (2021) · European Heart Journal

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 3